CorMedix Inc. (CRMD)

Market Cap	771.34M
Revenue (ttm)	214.30M
Net Income (ttm)	162.50M
Shares Out	78.79M
EPS (ttm)	2.25
PE Ratio	4.35
Forward PE	3.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,919,803
Open	9.69
Previous Close	9.81
Day's Range	9.56 - 9.85
52-Week Range	5.60 - 17.43
Beta	1.31
Analysts	Strong Buy
Price Target	17.43 (+78.04%)
Earnings Date	Nov 12, 2025

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Height...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2010
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: CRMD
• Website: https://www.cormedix.com

Analyst Summary

According to 7 analysts, the average rating for CRMD stock is "Strong Buy." The 12-month stock price target is $17.43, which is an increase of 78.04% from the latest price.

Price Target

$17.43

(78.04% upside)

Analyst Consensus: Strong Buy